 SAN DIEGO--BUSINESS WIRE--- GOSS--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two CNS-penetrant Brutons tyrosine kinase BTK inhibitors to its product candidate pipeline. Gossamer plans to initiate first-in-human studies of the first of these candidates, GB5121, in the fourth quarter of 2021. G 